Daix (France), January 15, 2021 – Inventiva (Euronext Paris and Nasdaq: IVA), a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of non-alcoholic steatohepatitis (NASH), mucopolysaccharidoses (MPS) and other diseases with significant unmet medical need, today announced the half-year report of its liquidity contract with Kepler Cheuvreux.

Original post:
Half-Year Review of Inventiva’s Liquidity Contract with Kepler Cheuvreux

Related Post

Leave a comment

Your email address will not be published. Required fields are marked *